Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE AND HYDROCHLOROTHIAZIDE versus HYDRO RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE AND HYDROCHLOROTHIAZIDE versus HYDRO RX.
HYDRALAZINE AND HYDROCHLOROTHIAZIDE vs HYDRO-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting smooth muscle vasodilator that relaxes arterioles, reducing peripheral resistance. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis, decreased plasma volume, and vasodilation. It also reduces peripheral vascular resistance.
Oral: 1 tablet (hydralazine 25 mg / hydrochlorothiazide 25 mg) 1-2 times daily. Maximum: hydralazine 200 mg/day, hydrochlorothiazide 50 mg/day.
Initial: 25 mg orally once daily; may increase to 50 mg once daily after 2 weeks based on response. Maximum: 50 mg daily.
None Documented
None Documented
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); extended in renal impairment. Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; extended to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Hydralazine: 80-90% renal (mostly as metabolites), <10% unchanged. Hydrochlorothiazide: 95-99% renal (unchanged).
Renal excretion of unchanged drug accounts for 60% of elimination; biliary/fecal excretion accounts for 30%; 10% metabolized.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic